Quote this publication Share Print

MEKINIST (trametinib), protein kinase inhibitor

ONCOLOGY - New indication
Opinions on drugs - Posted on Mar 18 2016

Reason for request

Inclusion

Moderate improvement as first-line treatment of unresectable or metastatic melanoma, in patients with a BRAF V600 mutation

  • MEKINIST now has Marketing Authorisation in combination with dabrafenib, in the treatment of adults with unresectable or metastatic melanoma with a BRAF V600 mutation.
  • Combining MEKINIST with dabrafenib improves progression-free survival and overall survival in comparison with dabrafenib alone.

Clinical Benefit

Substantial

-


Clinical Added Value

moderate

-


Therapeutic use

-

-

 

Contact Us

Évaluation des médicaments